372 related articles for article (PubMed ID: 25742482)
1. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
[TBL] [Abstract][Full Text] [Related]
2. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer.
Kiesslich T; Mayr C; Wachter J; Bach D; Fuereder J; Wagner A; Alinger B; Pichler M; Di Fazio P; Ocker M; Berr F; Neureiter D
Mol Cell Biochem; 2014 Nov; 396(1-2):257-68. PubMed ID: 25064451
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.
Li SH; Fu J; Watkins DN; Srivastava RK; Shankar S
Mol Cell Biochem; 2013 Jan; 373(1-2):217-27. PubMed ID: 23129257
[TBL] [Abstract][Full Text] [Related]
7. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
8. mTOR Inhibitors in Advanced Biliary Tract Cancers.
Wu CE; Chen MH; Yeh CN
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30682771
[TBL] [Abstract][Full Text] [Related]
9. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
10. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
[TBL] [Abstract][Full Text] [Related]
11. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
18. The crosstalk of mTOR/S6K1 and Hedgehog pathways.
Wang Y; Ding Q; Yen CJ; Xia W; Izzo JG; Lang JY; Li CW; Hsu JL; Miller SA; Wang X; Lee DF; Hsu JM; Huo L; Labaff AM; Liu D; Huang TH; Lai CC; Tsai FJ; Chang WC; Chen CH; Wu TT; Buttar NS; Wang KK; Wu Y; Wang H; Ajani J; Hung MC
Cancer Cell; 2012 Mar; 21(3):374-87. PubMed ID: 22439934
[TBL] [Abstract][Full Text] [Related]
19. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Graab U; Hahn H; Fulda S
Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
